利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性  

Clinical efficacy and safety of liraglutide in the treatment of patients with obesity and type 2 diabetes

作　　者：刘佳楠[1] 董宇[1] LIU Jia'nan;DONG Yu(Department of Pharmacy,the Central Hospital of Jiamusi City in Heilongjiang Province,Jiamusi 154002,China)

机构地区：[1]黑龙江省佳木斯市中心医院药剂科,黑龙江佳木斯154002

出　　处：《中国现代医生》2020年第15期127-130,共4页China Modern Doctor

摘　　要：目的探讨利拉鲁肽治疗肥胖2型糖尿病患者的临床疗效及安全性。方法选择2019年3~4月在我院诊断治疗的2型糖尿病患者100例为研究对象,BMI≥28 kg/m2。随机分为观察组与对照组各50例。对照组给予盐酸二甲双胍缓释片治疗,观察组在此基础上加用利拉鲁肽注射液治疗。比较两组治疗后血糖水平、体质量、BMI、腰围及不良反应。结果(1)治疗后,两组FBG、2 h PBG、HbA1c水平均较治疗前显著下降(P<0.05);治疗后,观察组FBG、2 h PBG、HbA1c水平显著低于对照组(P<0.05)。(2)两组治疗后体质量、BMI、腰围均较治疗前显著下降(P<0.05);治疗后观察组体质量、BMI、腰围均显著低于对照组(P<0.05)。(3)两组治疗期间不良反应比较差异无统计学意义(P>0.05)。结论利拉鲁肽治疗肥胖2型糖尿病具有较好的临床疗效及安全性。Objective To explore the clinical efficacy and safety of liraglutide in the treatment of patients with obesity and type 2 diabetes.Methods 100 patients with type 2 diabetes who were diagnosed and treated in our hospital from March to April 2019 were selected as the research subjects,with BMI≥28 kg/m2.They were randomly divided into observation group and control group,with 50 cases in each group.The control group was given metformin hydrochloride sustained-release tablets,and the observation group was given liraglutide injection on the basis of the control group.The blood glucose level,body mass,BMI,waist circumference and adverse reactions were compared between the two groups after treatment.Results(1)After treatment,the levels of FBG,2 h PBG and HbA1c in the two groups were significantly lower than those before treatment(P<0.05);after treatment,the levels of FBG,2 h PBG and HbA1c in the observation group were significantly lower than those in the control group(P<0.05).(2)The body weight,BMI and waist circumference in both groups after treatment were significantly decreased compared with those before treatment(P<0.05);the body mass,BMI and waist circumference in the observation group were significantly lower than those in the control group after treatment(P<0.05).(3)There was no statistically significant difference in adverse reactions between the two groups during treatment(P>0.05).Conclusion Liraglutide has a good clinical efficacy and safety in the treatment of obesity complicated with type 2 diabetes.

关 键 词：肥胖 2型糖尿病 GLP-1受体激动剂 利拉鲁肽 盐酸二甲双胍缓释片 

分 类 号：R587.1[医药卫生—内分泌]